In addition, XTL Biopharmaceuticals (Valley Cottage, NY, USA) is developing XTL-6865, a combination of two fully human mAbs (Ab68 and Ab65) that target the HCV E2 envelope protein. Phase 1 results ...

Also, most of the bNAbs from these chronically infected donors targeted a specific region of the hepatitis C virus, namely the front layer of the so-called E2 protein. The immune system in ...

The diversity of HCV makes immunotherapy or vaccine design very difficult. Law et al. have identified broadly neutralizing antibodies from a human with hepatitis C and demonstrated their HCV ...

Only mice inoculated with the plasmid expressing core, E1, and E2 under the EF-1promoter generated HCV-specific effector responses against all three proteins after a single immunization.

Indeed, HCV has been identified as one of the globally ... to mimic specific regions of the viral glycoproteins E1 and E2, known as neutralization epitopes. These were transferred onto synthetic ...